Eolo Pharma focuses on the prevention and treatment of metabolic disorders and cardiovascular diseases of chronic inflammatory origin. The team has developed so far more than 10 modified nutraceuticals to improve their anti-inflammatory properties, some of them already patented in the USA.
ImValv provides a novel solution to the treatment of Glaucoma. The company has developed the first active miniature valves to be implanted in the patient’s eye. These valves can control the intraocular fluid release thus reducing pressure, and can be opened and closed at will.
BioDrone is the first ag-tech company to provide an integrated pest monitoring and control service. Through intelligent traps monitoring the presence of pests 24/7, the system keeps insect populations low by using drones to precisely spray infected areas.
RadBio is a biopharmaceutical company that has identified and patented a new biomarker for rheumatoid arthritis (RA) diagnosis and a potential treatment for RA, liver fibrosis and certain cancers.
ViewMind uses eye-tracking technology to identify the onset of Alzheimer’s Disease in it's pre-symptomatic stage, through a 10 minutes, non-invasive, standardized and automatized neurocognitive evaluation.
Phylumtech is a Lab-as-a-Service company that has developed an automated in-vivo drug screening platform for better discovery of new compounds. It is the first cloud-based company running high-throughput in-vivo screening.
Crinsurance aims to revolutionize the safety and reliability of the cryopreservation of biological samples. Its solution removes human error from the equation in the preservation of stem cells, semen and embryos.
Selectivity's goal is to democratize the access to infertility treatments worldwide. Based on microfluidics technology, the company has developed a device that allows quick and simple selection of spermatozoa with the highest fertilization potential. The solution is designed for use in a clinic or even at home.
Synvax is developing a universal platform for the design and production of live-attenuated vaccines (LAVs) for RNA viruses. The company uses synthetic biology to genetically modify the viral genome, attenuating the virus while obtaining an identical immune response as unmodified viruses.